Investing.comDoubao · 实盘可交易 · 做空市场:美股▼ 亏 -3.19% · 已结算把握 6/10
北京时间·🕒 发布 04:12:58·⟳ 抓取 04:13:29 +31s·⚡ 决策 10-14 04:16:47 +3m18s·13.7 天前
Biomea Fusion口服GLP-1药物BMF-650一期减重数据：最佳队列受禁闭条件干扰、门诊疗效偏弱，公司寻求战略合作，盘后续跌约14%
数据核心亮点被公司自行披露的安慰剂/进食干扰削弱，门诊疗效弱于注射类及领先口服GLP-1，且附加毒理研究延迟开发、公司无合作方签约而仅表态寻求合作；市场在数据发布当日RTH已跌7.35%、盘后再跌14.25%并触及1美元，方向得到价格确认，满足直接、实质负面催化且置信度≥4，故以小仓SHORT参与，但因微盘流动性差且已大跌而控制仓位。
📄 原文Investing.com↗ 原文
Biomea Fusion reports weight loss data from oral GLP-1 trial
U.S. stocks slip slightly on tech weakness; Dow turns negative amid bank earnings SAN CARLOS, Calif. - Biomea Fusion, I…
▼ 亏 -3.19%入场 10-13 盘后首笔 @0.971 → 离场 10-14 开盘 @0.999
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(做空:价格在入场线下方)、绿底 = 亏
💡 交易逻辑一期减重亮点被安慰剂干扰、门诊疗效弱且寻求合作，盘后崩14%
怎么做空 开盘做空 不设价格下限（市价成交）
怎么平空 止盈 -15%(半仓)/-30%(清仓) · 止损 +15% · 时间止损 3日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做空 BMEA.US Biomea Fusion
5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)
- 发布 10-14 04:12 北京(美东 10-13 16:12)
- 抓取 10-14 04:13 北京(美东 10-13 16:13)
- 入场 10-14 04:16 北京(美东 10-13 16:16) · 盘后首笔 @0.971
- 决策 10-14 04:16 北京(美东 10-13 16:16)
- 离场 10-14 21:30 北京(美东 10-14 09:30) · 开盘 @0.999
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做空 BMEA.US Biomea Fusion
| 收益状态 | -3.19% 已平仓 |
|---|---|
| 进场成交 | 2026-10-13 · 盘后首笔 · 10-14 04:16 北京 · @0.9709 · 成交 45% |
| 离场成交 | 2026-10-14 · 开盘 · @0.9987 |
| 毛收益 | -2.86% |
| 成本 | +0.33% |
| 净收益 | -3.19% |
| 计入收益 | -1.43% |
| 建仓日 | 2026-10-13 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 20:10
研究档案
结论摘要
BMF-650一期最佳减重数据被禁闭条件和安慰剂组异常减重证伪含金量，门诊队列仅1.5%-3.2%且需补长期毒理，公司改为寻求合作被解读为独立开发能力/资金不足；BMEA盘后再跌14%，小仓做空次日开盘。
🔎 新鲜度:最早出现 2026-10-13 · 扩散 low · price-in 风险 medium ↗
消息传播链
- 节点
关键理由
- 最高6.1%减重组为禁闭条件所得，两名安慰剂受试者低热量摄入即出现相近减重，公司自认干扰，真实世界疗效只有门诊1.5%-3.2%/4周，显著弱于主流GLP-1
- 微盘股（市值约9100万美元）核心管线一期弱于预期+开发延迟+寻求合作，通常引发卖方下调、融资稀释担忧和生物科技散户止损的持续重估
主要风险
- 盘后已跌14%且盘中已跌7.35%，次日可能低开后出现超卖反弹或空头回补，微盘股波动剧烈
- 若公司宣布已签约知名合作方或后续披露更强的队列扩展数据，逻辑将被证伪，需基本面退出
反向证据
- 做空前查反向 · 来源 web · 影响 none
未检索到已签约合作方、药企背书或看多解读；intends to position for strategic partnership仅为意向，无交易对手确认
检索:BMF-650 strategic partnership deal positive analyst note October 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-13 · 影响 weakens
安全性数据干净（无严重AE、无停药、恶心17.5%）是数据中唯一正面项，可能缓和部分跌幅，但减重疗效才是减重药估值核心，不构成对空头逻辑的反转
检索:BMF-650 safety tolerability no discontinuations adverse events 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使仓位降为small、收紧止损与3日时限，不改变做空方向
方向:无可用对齐先例：本轮检索未获得可锚定首发时刻的同类口服GLP-1一期读出案例的一手首发链接，不以记忆编造价格反应
涨幅量级:幅度改由公司市值（约9100万美元）、盘后已实现的-14%重定价和微盘生物科技事件波动结构保守校准
形态:无法以先例判断见光死模式；本事件的方向确认主要来自数据文本弱点与盘后真实价格
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 9 ms
{"result": "search_processed_events:agent query=`biomea fusion bmf-650 oral glp-1 phase 1 weight loss data | biomea fusion oral small molecule glp-1 receptor agonist trial results strategic partnership | bmea bmf-650 6.1% weight `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{ - stock_quote 成功 stock_tools HTTP · 419 ms
{ - web_search 成功 doubao_search · 1,056 ms
豆包搜索结果（原始查询:Biomea Fusion BMF-650 Phase 1 weight loss data press release October 2026；API SearchType:web） - web_search 成功 doubao_search · 1,050 ms
豆包搜索结果（原始查询:BMEA stock BMF-650 oral GLP-1 data reaction analyst confinement cohort；API SearchType:web）
原文全文
展开原文 · 2,071 字
U.S. stocks slip slightly on tech weakness; Dow turns negative amid bank earnings
SAN CARLOS, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA) announced results from its Phase 1 trial of BMF-650, an oral small-molecule GLP-1 receptor agonist, according to a press release statement issued today.
The randomized, double-blind, placebo-controlled study evaluated BMF-650 in overweight or obese adults across five multiple ascending dose cohorts over four weeks. In outpatient Cohorts 1-4, mean weight reduction at Day 29 ranged from 1.5% to 3.2%, compared with 0.1% for pooled placebo. At doses of 200 mg or higher once daily, mean weekly weight reduction was approximately 0.97 kg across these cohorts.
A fifth cohort conducted under confinement showed mean weight reduction of 6.1% (6.2 kg) at Day 29, averaging approximately 1.55 kg per week. Participants received 200 mg once daily for one week followed by 400 mg once daily for three weeks. The company noted that confinement appeared to affect eating behavior, with two placebo participants showing similar weight reduction while consuming only approximately 33% of the 2,100 kcal/day provided.
Across all five active-dose cohorts totaling 40 participants, all treatment-emergent adverse events were mild or moderate. The company reported no severe or serious adverse events, no dose modifications, and no study discontinuations related to adverse events. In Cohort 5, nausea and vomiting were each reported in 12.5% of participants, constipation in 25%, and diarrhea in none. Across all cohorts, nausea occurred in 17.5% of participants, vomiting in 7.5%, constipation in 10%, and diarrhea in 5%.
The study evaluated safety and tolerability as co-primary endpoints, with pharmacokinetics, pharmacodynamics, and weight reduction as secondary endpoints. Additional clinical development will require longer-term toxicology studies. The company stated it intends to position the program for a strategic partnership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN CARLOS, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA) announced results from its Phase 1 trial of BMF-650, an oral small-molecule GLP-1 receptor agonist, according to a press release statement issued today.
The randomized, double-blind, placebo-controlled study evaluated BMF-650 in overweight or obese adults across five multiple ascending dose cohorts over four weeks. In outpatient Cohorts 1-4, mean weight reduction at Day 29 ranged from 1.5% to 3.2%, compared with 0.1% for pooled placebo. At doses of 200 mg or higher once daily, mean weekly weight reduction was approximately 0.97 kg across these cohorts.
A fifth cohort conducted under confinement showed mean weight reduction of 6.1% (6.2 kg) at Day 29, averaging approximately 1.55 kg per week. Participants received 200 mg once daily for one week followed by 400 mg once daily for three weeks. The company noted that confinement appeared to affect eating behavior, with two placebo participants showing similar weight reduction while consuming only approximately 33% of the 2,100 kcal/day provided.
Across all five active-dose cohorts totaling 40 participants, all treatment-emergent adverse events were mild or moderate. The company reported no severe or serious adverse events, no dose modifications, and no study discontinuations related to adverse events. In Cohort 5, nausea and vomiting were each reported in 12.5% of participants, constipation in 25%, and diarrhea in none. Across all cohorts, nausea occurred in 17.5% of participants, vomiting in 7.5%, constipation in 10%, and diarrhea in 5%.
The study evaluated safety and tolerability as co-primary endpoints, with pharmacokinetics, pharmacodynamics, and weight reduction as secondary endpoints. Additional clinical development will require longer-term toxicology studies. The company stated it intends to position the program for a strategic partnership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6865d967e0· 2026-10-14 04:16 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前